Stereotactic body radiation therapy for sarcoma pulmonary metastases.

ABSTRACT:

Background/purpose

Stereotactic body radiation therapy (SBRT) is standard for patients with inoperable early-stage NSCLC. We hypothesized that SBRT for sarcoma pulmonary metastases would achieve high rates of local control with acceptable toxicity and that patients with oligometastatic disease may achieve prolonged survival following SBRT.

Materials/methods

This retrospective review included consecutive patients at our institution treated with SBRT for sarcoma pulmonary metastases. Cumulative incidence of local failure (LF) was estimated using a competing risks framework.

Results

We identified 66 patients treated to 95 pulmonary metastases with SBRT. The median follow-up from the time of SBRT was 36 months (95% CI 34 - 53 months). The cumulative incidence of LF at 12

SUBMITTER: Lebow ES 

PROVIDER: S-EPMC11225867 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature